Purdue Pharma Company Profile

✉ Email this page to a colleague

PURDUE PHARMA has twelve approved drugs.

There are sixty-nine US patents protecting PURDUE PHARMA drugs.

There are five hundred and seventeen patent family members on PURDUE PHARMA drugs in fifty-one countries and eight supplementary protection certificates in five countries.

International Patents:	517
US Patents:	69
Tradenames:	12
Ingredients:	11
NDAs:	12
Patent Litigation for Purdue Pharma:	See patent lawsuits for Purdue Pharma
PTAB Cases with Purdue Pharma as petitioner:	See PTAB cases with Purdue Pharma as petitioner
PTAB Cases with Purdue Pharma as patent owner:	See PTAB cases with Purdue Pharma as patent owner

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-004	Apr 5, 2010		RX	Yes	No	9,492,392	⤷ Subscribe	Y			⤷ Subscribe
Purdue Pharma Lp	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-005	Nov 20, 2014	AB	RX	Yes	No	9,770,416	⤷ Subscribe	Y			⤷ Subscribe
Purdue Pharma Lp	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-001	Nov 20, 2014	AB	RX	Yes	Yes	9,545,380	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-005	Apr 5, 2010	9,060,976	⤷ Subscribe
Purdue Pharma Lp	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-002	Nov 20, 2014	9,669,024	⤷ Subscribe
Purdue Pharma Lp	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-005	Nov 20, 2014	9,198,863	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Sublingual Tablets	1.75 mg and 3.5 mg	➤ Subscribe	2012-04-10
➤ Subscribe	Transdermal System	15 mcg/hr	➤ Subscribe	2013-12-16
➤ Subscribe	Extended-release Tablets	30 mg, 40 mg, 80 mg, and 100 mg	➤ Subscribe	2015-05-08
➤ Subscribe	Extended-release Tablets	30 mg and 60 mg	➤ Subscribe	2007-01-03
➤ Subscribe	Extended-release Tablets	100 mg, 200 mg and 300 mg	➤ Subscribe	2009-06-18
➤ Subscribe	Transdermal System	5 mcg/hr, 10 mcg/hr, and 20 mcg/hr	➤ Subscribe	2013-06-06
➤ Subscribe	Extended-release Tablets	20 mg, 60 mg, and 120 mg	➤ Subscribe	2015-04-15
➤ Subscribe	Extended-release Tablets	15 mg	➤ Subscribe	2007-02-15

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2236132	92636	Luxembourg	⤷ Subscribe	PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
0566709	SPC/GB04/012	United Kingdom	⤷ Subscribe	PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925
1685839	92292	Luxembourg	⤷ Subscribe	PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.